Joint development of anti-cancer drug research firms

 The National Cancer Center President, Lee Jin-soo introduced the Bridging & Development Cancer Program Therapeutics with System Integration as a research foundation for a new anti-cancer drug. Kim, In –cheo is the manager of this organization. This program was designated by the ministry of Health and Welfare on January 26th and a material transfer agreement (MTA) with Sanofi Aventis Korea was developed ( for joint development research of a new anti-cancer drug.

According to this agreement, the program will conduct all clinical trials for a toxicity test on the candidates. These contain substances for new anti-drugs that will further be developed by Sanofi Aventis Korea, who will verify its efficacy.

Program Manager Kim, In-cheol spoke of the significance of this agreement, saying “joint development with a multinational pharmaceutical firm is the most effective way for us to overcome Korea’s limited resources and infrastructure for new drug development and secure global competitiveness in the new drug area. This agreement marks the first step in such an endeavor.”

For full article see Korea IT Times.